Lanean...
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
The management of advanced renal cell carcinoma (RCC) has dramatically changed over the past decade. Therapies that target the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways have considerably expanded treatment options; however, most patients with advance...
Gorde:
| Argitaratua izan da: | Nat Rev Urol |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5532875/ https://ncbi.nlm.nih.gov/pubmed/27324121 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrurol.2016.103 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|